16:04 EDT Stoke Therapeutics (STOK) files $400M mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- Positive Outlook on Stoke Therapeutics: Buy Rating Affirmed Amid Promising Phase 3 Trial for Dravet Syndrome Treatment
- Stoke Therapeutics Advances Phase 3 Study for Dravet Syndrome Treatment
- Stoke Therapeutics Adopts Key Proposals at Annual Meeting
- Stoke Therapeutics Launches Phase 3 EMPEROR Study
- Promising Outlook for Stoke Therapeutics: Buy Rating Backed by Phase 3 Trial Progress and Strong Financial Position